How a giant Amazonian frog could help save millions of lives
The skin of a frog that lives in the Amazon rainforest could help solve the antibiotic resistance crisis. Image: REUTERS/Pichi Chuang
Antimicrobial resistance, which essentially renders antibiotics ineffective, is “the biggest crisis of the 21st century,” according to Space Time Ventures chairman Juan Carlos Castilla-Rubio, who spoke at the World Economic Forum Annual Meeting in Davos, Switzerland, in January.
This resistance is due largely to antibiotics being overused in medicine and agriculture. Furthermore, no new class of antibiotics has been introduced since 1987, and without new antibiotics being developed deaths from antimicrobial resistance will increase to 10 million people per year by 2050, according to research commissioned by the UK government.
Castilla-Rubio, however, pointed out that bio-innovation could help save lives.
Could frogs hold the answer?
Castilla-Rubio explained that giant monkey frogs could be a source of new antibiotics. Data from the National Center for Biotechnology Information shows frog skin is the source of 300 different antimicrobial peptides, which target viruses and bacteria.
And it’s not just frogs. Another possible solution to the antibiotics crisis can be found in most ants, according to a study published by The Royal Society, which reveals that many ant species also produce antimicrobial secretions. Those that don’t, the researchers say, have developed alternative strategies to defend themselves, which could also be beneficial to humans.
Castilla-Rubio added that the Amazon rainforest could be a source of up to 25% – or more than 282,000 – of the known natural compounds that could be used to create new and improved medicines, including antibiotics.
Using the natural world as a source of inspiration and innovation could also help unlock a diversity-based “bio-economy” worth trillions of US dollars, Castilla-Rubio said.
Dealing with the threats
Castilla-Rubio warned that to unlock this bio-economy and make it inclusive, we need to deal with three challenges head-on.
Firstly, deforestation, which severely threatens the Amazon. Secondly, it is critical that sharing information benefits all people fairly and equitably. Lastly, we need to deal with very complex regulations "because biology is increasingly digital and increasingly engineered,” according to Castilla-Rubio.
The Amazon Bank of Codes
In an effort to create a solution, Castilla-Rubio helped launch the Amazon Bank of Codes, an open “public good” digital platform used to map the biological assets and functions of the Amazon, making them visible in a fair and equitable way.
“Because we are mapping life in the Amazon, the assets will be accessible and available to innovators, and because we will register these assets on a blockchain, you will know that when you source components of innovation for commercial plans, you are sourcing innovation that is sustainable,” Castilla-Rubio explained.
He hopes that once the benefits of the Amazon have been shared fairly and equitably, the bank will be replicated worldwide to form the Earth Bank of Codes, which will codify rights and obligations.
“You will know when you exploit [the Amazon's assets], you can share the benefits fairly with the countries of origin and with the custodians of nature," Castilla-Rubio said. "[Y]ou will have access to the ‘Wikipedia of life.’"
Don't miss any update on this topic
Create a free account and access your personalized content collection with our latest publications and analyses.
License and Republishing
World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
Stay up to date:
Global Health
Related topics:
The Agenda Weekly
A weekly update of the most important issues driving the global agenda
You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.
More on Health and Healthcare SystemsSee all
Naoko Tochibayashi and Mizuho Ota
November 7, 2024